Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cancer, infections and inflammatory disorders.

Medshine Discovery Inc. has identified androgen receptor antagonists reported to be useful for the treatment of androgenic alopecia.

Kymera Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 1 (DCAF1) binding moiety covalently linked to a bromodomain-containing protein 4 (BRD4; HUNK1) targeting moiety.

Neuroninn Biosciences Co. Ltd. has disclosed G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety, depression, Parkinson’s disease and more.

Light Horse Therapeutics Inc. has described transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Rulink Biopharma Co. Ltd. has synthesized integrin αvβ1, αvβ6 and/or αvβ8 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Nine Square Therapeutics Inc. has disclosed mucolipin-1 modulators reported to be useful for the treatment of metabolic disease, neurodegeneration, aging, immunological disorders, inflammatory disorders, cardiovascular disorders, lysosomal storage disease and cancer.

Nikang Therapeutics Inc. has described GTPase KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.